Profile data is unavailable for this security.
About the company
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
- Revenue in TWD (TTM)35.09m
- Net income in TWD-1.69bn
- Incorporated2006
- Employees--
- LocationPolaris Group LLCUgland HouseP.O. Box 309GRAND CAYMAN KY1-1104Cayman IslandsCYM
- Websitehttps://polarispharma.com/?lang=en
Mergers & acquisitions
| Acquired company | 6550:TAI since announced | Transaction value |
|---|---|---|
| British Cayman Islands Shanglinyang Pharmaceutical Co Ltd | -25.59% | 36.13m |
| Genovior Biotech Corp | -25.59% | 62.84m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polaris Group LLC | 35.09m | -1.69bn | 49.29bn | -- | -- | 6.76 | -- | 1,404.81 | -2.28 | -2.28 | 0.0472 | 9.78 | 0.0038 | -- | 4.58 | -- | -18.71 | -16.55 | -20.12 | -17.96 | -24.76 | -- | -4,904.26 | -12,960.21 | 12.67 | -- | 0.141 | -- | 16.18 | -- | -37.05 | -- | 50.45 | -- |
| PharmaEssentia Corp | 5.87bn | 442.09m | 221.25bn | 131.00 | 471.16 | 8.82 | 295.63 | 37.68 | 1.38 | 1.38 | 18.17 | 73.56 | 0.2681 | 0.5024 | 4.64 | -- | 2.02 | -16.79 | 2.32 | -19.66 | 88.58 | 76.47 | 7.53 | -79.56 | 11.67 | -- | 0.0444 | -- | 77.15 | 186.97 | 54.62 | -- | 66.34 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Jul 2024 | 10.04m | 1.35% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 3.53m | 0.47% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 1.43m | 0.19% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 913.00k | 0.12% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 610.57k | 0.08% |
| TIAA-CREF Investment Management LLCas of 31 May 2024 | 251.00k | 0.03% |
| Geode Capital Management LLCas of 31 May 2024 | 160.00k | 0.02% |
| Parametric Portfolio Associates LLCas of 31 May 2024 | 107.98k | 0.01% |
| State Street Global Advisors Ltd.as of 04 Jul 2024 | 75.00k | 0.01% |
| Yuanta Securities Investment Trust Co., Ltd.as of 05 Jul 2024 | 68.40k | 0.01% |
